Tweet
PLoS One
. 2025 Jul 3;20(7):e0327244.
doi: 10.1371/journal.pone.0327244. eCollection 2025. Time-series metabolomic profiling of SARS-CoV-2 infection: Possible prognostic biomarkers in patients in the ICU by ¹H-NMR analysis
Emir Matpan 1 , Ahmet Tarık Baykal 1 2 , Lütfi Telci 3 , Türker Kundak 4 , Mustafa Serteser 1 2
Affiliations
The global impact of SARS-CoV-2, which causes COVID-19, remains significant, being intensified by the emergence of variants. Comprehensive metabolomic studies aimed to elucidate the distinctive metabolic footprint of the virus. For critically ill patients with COVID-19 in the intensive care unit (ICU), longitudinal monitoring based on their prognosis is crucial to optimize treatment outcomes. This study retrospectively investigated the temporal changes in the metabolomic profiles of patients admitted to the ICU with COVID-19, who were categorized into three prognostic groups: healthy discharged (HD), polyneuropathic syndrome (PS), and Exitus. In total, 32 serum samples collected in April 2020 at regular intervals (four samples per patient) and stored at -80°C, were analyzed using proton nuclear magnetic resonance (1H-NMR) spectroscopy. Significant (p < 0.05) prognostic changes in creatine and tyrosine levels were revealed by two-way analysis of variance (ANOVA) and ANOVA-simultaneous component analysis (ASCA). Furthermore, supervised random forest analysis demonstrated excellent group prediction with a 21.9% out-of-bag error rate based on prognosis. Specifically, creatine levels were highest in the PS group, whereas tyrosine levels were highest in the Exitus group. However, no metabolite displayed significant changes over time. In addition, metabolic pathway analysis using the Kyoto Encyclopedia of Genes and Genomes database indicated that the most significantly impacted pathway (p < 0.05) across different prognostic groups was "phenylalanine, tyrosine and tryptophan biosynthesis." This preliminary study emphasizes the need for time-series analysis of samples from unvaccinated patients with varying prognoses, providing valuable insights into the metabolic impact of COVID-19.
. 2025 Jul 3;20(7):e0327244.
doi: 10.1371/journal.pone.0327244. eCollection 2025. Time-series metabolomic profiling of SARS-CoV-2 infection: Possible prognostic biomarkers in patients in the ICU by ¹H-NMR analysis
Emir Matpan 1 , Ahmet Tarık Baykal 1 2 , Lütfi Telci 3 , Türker Kundak 4 , Mustafa Serteser 1 2
Affiliations
- PMID: 40608744
- DOI: 10.1371/journal.pone.0327244
The global impact of SARS-CoV-2, which causes COVID-19, remains significant, being intensified by the emergence of variants. Comprehensive metabolomic studies aimed to elucidate the distinctive metabolic footprint of the virus. For critically ill patients with COVID-19 in the intensive care unit (ICU), longitudinal monitoring based on their prognosis is crucial to optimize treatment outcomes. This study retrospectively investigated the temporal changes in the metabolomic profiles of patients admitted to the ICU with COVID-19, who were categorized into three prognostic groups: healthy discharged (HD), polyneuropathic syndrome (PS), and Exitus. In total, 32 serum samples collected in April 2020 at regular intervals (four samples per patient) and stored at -80°C, were analyzed using proton nuclear magnetic resonance (1H-NMR) spectroscopy. Significant (p < 0.05) prognostic changes in creatine and tyrosine levels were revealed by two-way analysis of variance (ANOVA) and ANOVA-simultaneous component analysis (ASCA). Furthermore, supervised random forest analysis demonstrated excellent group prediction with a 21.9% out-of-bag error rate based on prognosis. Specifically, creatine levels were highest in the PS group, whereas tyrosine levels were highest in the Exitus group. However, no metabolite displayed significant changes over time. In addition, metabolic pathway analysis using the Kyoto Encyclopedia of Genes and Genomes database indicated that the most significantly impacted pathway (p < 0.05) across different prognostic groups was "phenylalanine, tyrosine and tryptophan biosynthesis." This preliminary study emphasizes the need for time-series analysis of samples from unvaccinated patients with varying prognoses, providing valuable insights into the metabolic impact of COVID-19.